Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.
| Title | Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Karlafti, E. F., Hatzitolios A. I., Karlaftis A. F., Baltatzi M. S., Koliakos G. G., & Savopoulos C. G. |
| Journal | J Pharm Bioallied Sci |
| Volume | 5 |
| Issue | 4 |
| Pagination | 253-6 |
| Date Published | 2013 Oct |
| ISSN | 0976-4879 |
| Abstract | Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys. |
| DOI | 10.4103/0975-7406.120067 |
| Alternate Journal | J Pharm Bioallied Sci |
| PubMed ID | 24302832 |
| PubMed Central ID | PMC3831737 |
